Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

CJC-1295 + Ipamorelin peptide iconCJC-1295 + Ipamorelin34 residues (approx.)YADAIFTQSYRKVLAQLSARKLLQDILSRAHXFKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

CJC-1295 + Ipamorelin

Beginner tier: 200 mcg, daily · 12w on / 4w off · community consensus

2 h half-life·Injection

Also known as: CJC/Ipa, CJC-1295/Ipamorelin, mod GRF 1-29 + Ipamorelin

Hundreds of threads on r/Peptides call this the cleanest growth hormone stack available without a prescription. CJC-1295 (No DAC) plus Ipamorelin is a pre-mixed blend hitting two separate pituitary receptors, GHRH and GHS-R1a; community reports describe a GH pulse that neither achieves alone. Ipamorelin's selectivity is the draw. Unlike GHRP-2 or GHRP-6, it didn't raise ACTH or cortisol in swine (Raun et al. 1998)[1]. Sleep improvements typically appear within seven to ten days. No published RCT has tested this exact combination. The evidence base leans on individual-component clinical data combined with community experience across thousands of users.

What Is CJC-1295 + Ipamorelin?

Deeper sleep in under two weeks. That's the benefit users mention first, and it's the reason CJC-1295 plus Ipamorelin (also called CJC/Ipa or modified GRF 1-29 plus Ipamorelin) has become the default GH secretagogue stack for anti-aging and body recomposition protocols.

The blend contains two peptides in a single vial. CJC-1295 without DAC is a 29-amino-acid GHRH analog. Ipamorelin is a pentapeptide ghrelin mimetic. Only ipamorelin has human data in the form used here. Gobburu's group [3] infused it into healthy men, and GH peaked at about 40 minutes. CJC-1295 without DAC has no published human trial. Teichman et al. (2006)[2] tested CJC-1295 with DAC, a different long-acting form. One injection raised GH 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days. In rats and swine, Raun's group [1] found ipamorelin released GH without raising ACTH or cortisol.

CJC-1295 sets the amplitude of the GH pulse through the GHRH receptor. Ipamorelin triggers the release through GHS-R1a. Together, the resulting pulse exceeds what either produces independently.

Community dosing uses three tiers of total blend per injection. Beginner is 200 mcg once daily, Moderate 300 mcg once daily, and Aggressive 600 mcg twice daily. Injections go in subcutaneously on an empty stomach, the once-daily dose before bed. The standard cycle runs 12 to 16 weeks on, 4 weeks off. Hundreds of r/Peptides threads (roughly 95,000 members) report consistent improvements in sleep quality, recovery speed, skin texture, and gradual fat loss over three to four months.

The limitation is straightforward: no published randomized controlled trial has studied this pre-mixed combination in humans. Combination benefit is mechanistically sound but clinically unquantified. All human GH-elevation data comes from each component tested separately.

How CJC-1295 + Ipamorelin Works

Two receptors, one coordinated pulse. That is the core idea.

CJC-1295 (No DAC) binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. This activates Gs-coupled adenylyl cyclase, raises intracellular cAMP, and primes the cell for GH synthesis. Think of it as loading the spring.

Ipamorelin binds a separate receptor: GHS-R1a. That activation runs through Gq/11 signaling. Intracellular calcium rises via IP3, directly triggering GH exocytosis. This pulls the trigger.

When both pathways fire at the same time, the GH pulse is larger than either agent produces alone. GHRH sets amplitude; the ghrelin mimetic sets timing. Gobburu et al. (1999)[3] mapped ipamorelin's pharmacokinetics in healthy men given 15-minute IV infusions. GH peaked at about 40 minutes, and ipamorelin's half-life was 2 hours.

Ipamorelin's selectivity separates it from older GHRPs. GHRP-2 and GHRP-6 also bind GHS-R1a, and in swine they raised ACTH and cortisol. Ipamorelin did not, even at doses over 200 times the amount needed for GH release (Raun et al. 1998)[1].

Downstream, the raised GH pulse stimulates hepatic IGF-1 production. IGF-1 drives anabolic effects in muscle, bone, and connective tissue. GH also activates hormone-sensitive lipase in adipocytes, promoting lipolysis. The combined release follows the body's natural pulsatile GH pattern rather than a sustained plateau, preserving negative feedback regulation through the hypothalamic-pituitary axis.

CJC-1295 + Ipamorelin Benefits

  • CJC-1295 plus Ipamorelin benefits center on clean GH release and the downstream effects it drives.
  • Dramatically improved sleep depth is the most consistently cited effect, with onset typically within 7 to 14 days. Community forums show this as the single most mentioned benefit across hundreds of threads on r/Peptides.
  • A cleaner hormonal profile than older GHRPs. In swine, ipamorelin left ACTH, cortisol and prolactin unchanged (Raun et al. 1998)[1]. Users credit that selectivity for tolerating 12 to 16 week cycles.
  • Gradual fat loss combined with lean mass gains over 3 to 4 months, particularly abdominal fat. Users on standard cycles report visible recomposition by weeks 8 to 12.
  • Faster recovery from training and injury. GH and IGF-1 elevation accelerates protein synthesis in muscle and connective tissue; community reports consistently place recovery improvement at weeks three through four.
  • Skin, hair, and nail quality improvements typically appear by month two. Collagen synthesis driven by sustained IGF-1 elevation produces visible changes that many users notice before body composition shifts.
  • Pre-mixed convenience: one vial, one injection, two pathways activated. The blend removes the complexity of sourcing and mixing two separate peptides.

CJC-1295 + Ipamorelin: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 9 key studies·Research only

CJC-1295 (No DAC) acts on the GHRH receptor but has no published human trial; the human CJC-1295 data come from the DAC form.

Dosing studied: 100–300 mcg per component per injection (200–600 mcg total blend), SC, once or twice daily; clinical studies dosed by body weight. CJC-1295 with DAC was given as single doses, or 2 to 3 doses 1 to 2 weeks apart, and was best tolerated at 30 or 60 mcg/kg SC (PMID 16352683). IV ipamorelin ran 4.21 to 140.45 nmol/kg (PMID 10496658)
Read the evidence (key study, limitations)

Ipamorelin released GH via GHS-R1a without raising ACTH or cortisol in swine, and a human PK study found a single GH peak [3]. No published RCT has tested the combination as a co-administered blend. The combined effect is mechanistically sound (GHRH + ghrelin receptor dual-pathway) but clinically unquantified.

Key Study

Teichman et al. 2006 (PMID 16352683) tested CJC-1295 with DAC, not the No DAC form in this blend. One SC injection raised GH 2–10x for 6+ days and IGF-1 1.5–3x for 9–11 days in healthy adults. Raun et al. 1998 (PMID 9849822): ipamorelin released GH without raising ACTH or cortisol in swine, even at over 200 times its GH-releasing dose.

Limitations

All human GH-elevation data is for individual components, not the pre-mixed blend. CJC-1295 studies used the With-DAC form (longer half-life); No DAC combination dosing extrapolated by community. No Phase III trial for either compound. No long-term (>6 month) safety data in humans.

Community Experience
Strong
4.2/5
Based on hundreds of r/Peptides threads

Widely regarded as the best "clean" GH stack: high satisfaction for sleep quality, body recomposition, and recovery.

Community dosing: 200–600 mcg total blend per injection in three tiers: 200 mcg once daily (Beginner), 300 mcg once daily (Moderate), 600 mcg 2x daily (Aggressive); the once-daily tiers dose at bedtime, some add a second injection on training days
Read the reports (what users report 5, common issues 5)

Bedtime dosing on empty stomach is near-universal. Strong consensus on No DAC over DAC for daily-pulse protocols.

What users report (5)
  • Dramatically improved sleep depth: most commonly cited, onset within 1–2 weeks
  • Clean GH profile: no hunger spike, no cortisol or prolactin elevation (vs GHRP-2/GHRP-6)
  • Gradual fat loss + lean mass gain over 3–4 months
  • Faster recovery from training and injury
  • Improved skin quality and sense of well-being by month 2
Common issues (5)
  • Water retention / mild edema in hands, feet, wrists: common in weeks 1–4
  • Slow timeline: users expecting fast results often quit before meaningful changes appear (minimum 4–6 weeks)
  • DAC vs. No DAC confusion: products mislabeled; DAC form has 6–8 day half-life, not suitable for daily pulse dosing
  • Tingling and numbness in extremities: GH-induced fluid shifts; resolves after initial weeks
  • Cost and consistency of pre-mixed blends; purity varies significantly by brand
Partially Aligned

Human trials studied each part on its own. CJC-1295 with DAC, not the No DAC form in this blend, raised GH and IGF-1 in healthy adults (PMID 16352683). IV ipamorelin raised GH in a human PK study (PMID 10496658). No trial has tested the blend. Community dosing (200 to 600 mcg of total blend per injection) cannot be compared directly with trial doses, which were per kilogram. Main divergence: community uses daily No DAC pulses while the only long-duration human data used the DAC form.

CJC-1295 + Ipamorelin Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner200 mcg
DailyTrack
Moderate300 mcg
DailyTrack
Aggressive600 mcg
2x DailyTrack
Note:

Standard vials come as 10 mg total (5 mg CJC-1295 No DAC plus 5 mg Ipamorelin). Add 2 mL bacteriostatic water. That gives you 5,000 mcg/mL total peptide concentration.

At 200 mcg per dose: 0.04 mL = 4 units on a 100-unit insulin syringe. One vial lasts about 50 doses. At 300 mcg: 0.06 mL = 6 units. One vial gives about 33 doses. At 600 mcg: 0.12 mL = 12 units. One vial yields about 16 injections.

Empty stomach is non-negotiable. Food within two hours raises somatostatin, which directly blunts the GH response. Wait at least 30 minutes after injecting before eating.

The biggest beginner mistake: using "CJC-1295" without confirming it is the No DAC version. The DAC form has a 6 to 8 day half-life and should only be dosed once or twice per week. Daily dosing of the DAC form creates continuous non-pulsatile GH elevation, defeating the purpose.

Store reconstituted vials at 2 to 8 degrees Celsius. Use within 21 to 28 days. Cloudiness or particulates means something went wrong; don't inject.

Cycling Protocol

On Period
12 weeks
Off Period
4 weeks

Standard protocol is 12-16 weeks on, followed by 4 weeks off to maintain GHS-R1a receptor sensitivity. Some users run 5 days on / 2 days off within each cycle week. Dose before bed on an empty stomach (at least 2 hours fasted) to align with natural nocturnal GH pulsatility. Avoid eating for 30 minutes post-injection to prevent insulin-mediated blunting of GH release.

Calculate your CJC-1295 + Ipamorelin dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

CJC-1295 + Ipamorelin Protocols by Goal

beginnerCommunity12 weeks on, 4 weeks off
Single daily bedtime injection
Wk 1–12
200 mcg total blend (100 mcg CJC-1295 No DAC + 100 mcg Ipamorelin) · Once daily (bedtime) · Subcutaneous

Expected: Improved sleep depth by week 2; mild fat loss and recovery improvement by weeks 6–8; body composition shifts by end of cycle

Monitor: Baseline and post-cycle IGF-1 recommended if running multiple cycles; fasting glucose monitoring if diabetic risk factors present

How to Use CJC-1295 + Ipamorelin

  1. 1
    Step 1

    Gather supplies: reconstituted CJC/Ipa vial, 29 to 31 gauge insulin syringe (100-unit), alcohol swabs.

  2. 2
    Clean the vial stopper with an alcohol swab

    Draw air into the syringe equal to your dose volume, inject air into the vial, then draw your dose.

  3. 3
    For a 200 mcg dose: draw to the 4-unit mark (0.04 mL)

    For 300 mcg: 6 units (0.06 mL). For 600 mcg: 12 units (0.12 mL). These numbers assume a 10 mg vial reconstituted with 2 mL bacteriostatic water (5,000 mcg/mL).

  4. 4
    Step 4

    Choose your injection site: lower abdomen about two inches from the navel, or upper outer thigh. Clean the site with an alcohol swab.

  5. 5
    Step 5

    Pinch a fold of skin, insert the needle at a 45 to 90 degree angle, and inject slowly. Release the skin fold after withdrawing.

  6. 6
    Step 6

    Rotate injection sites each time to prevent lipodystrophy.

  7. 7
    Step 7

    Timing: 30 minutes before sleep on an empty stomach (minimum 2 hours fasted). Don't eat for 30 minutes after injection. Optional second dose on training days, post-workout while still fasted.

  8. 8
    Step 8

    Return the vial to the refrigerator immediately (2 to 8 degrees Celsius).

Alternative Routes

Subcutaneous injection (SC)

Reference route; all dosing guidelines apply

Lower abdomen or upper thigh preferred; 29–31 gauge insulin syringe; inject on empty stomach. SC bioavailability has not been measured in humans for either component

Intranasal

Absorption highly variable; no validated dose for the blend

Intranasal GHRP-2 has been studied in 15 children (Pihoker 1997, PMID 9390009). Nasal ipamorelin has rat data only, about 20% bioavailability (Johansen 1998, PMID 9879640), and CJC-1295 has none. Not recommended: no reliable dose conversion available for the blend.

Mixing your own vial? Use the CJC-1295 + Ipamorelin reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

CJC-1295 + Ipamorelin Stacking Protocols

Works With

Avoid

GHRP-2

Adding a second GHS-R1a agonist (GHRP-2) on top of Ipamorelin stacks two drugs on one receptor, with increased cortisol, prolactin, and appetite stimulation; raises IGF-1 unpredictably. Not recommended without medical supervision.

GHRP-6

Same receptor competition/addition concern as GHRP-2 plus significant hunger amplification. Unlikely to add meaningful benefit over ipamorelin already in the blend.

CJC-1295 with DAC

CJC-1295 DAC has a 6–8 day half-life and is not dosed daily: combining with the No DAC blend creates dosing schedule confusion and unpredictable GHRH receptor stimulation duration.

Do not combine
MK-677 (Ibutamoren)

MK-677 is a long-acting oral GHS-R1a agonist (t½ ~24h); stacking with Ipamorelin in this blend creates continuous receptor activation, negating the pulsatile GH release benefit and substantially elevating IGF-1 and cortisol. Common community mistake.

Estimated Cost

Generic / Research
$60–$100 per 10mg pre-mixed vial (5mg CJC-1295 No DAC + 5mg Ipamorelin), research-grade market range; at 300 mcg/day (Moderate tier), one vial lasts ~33 days (~$1.80–$3.00/day); at 600 mcg twice daily (Aggressive tier, 1,200 mcg/day), ~8 days (~$7.20–$12.00/day)
Compounded
No listed 503A route: neither component is on FDA's 503A bulks list (Category 2 page captured Oct 6, 2026)
Brand Price
$300–$600/month via telehealth/clinic programs (includes medical supervision, supplies, and shipping); premium concierge clinics charge $500–$800+/month

Pricing updated 2026-04-09

CJC-1295 + Ipamorelin Side Effects

GH antagonizes insulin. That is the most important safety consideration with any GH secretagogue stack, and it deserves to lead this section.

Raised fasting glucose, worsening insulin sensitivity, and rising HOMA-IR are real risks at higher doses and in users with pre-diabetic markers. If fasting glucose rises more than 20 mg/dL from baseline, reduce the dose or stop the cycle. Pre-diabetic users should monitor HbA1c across consecutive cycles.

Water retention is the most common complaint in the first four weeks. Mild edema in the hands, wrists, and feet affects a large percentage of users. GH promotes sodium retention in the kidneys. Most cases resolve after the initial adaptation period. If edema persists beyond week four, reducing the dose by 25 to 50 percent and limiting injection to once-daily bedtime typically resolves it.

Tingling and numbness in the fingers and hands reflect GH-mediated fluid shifts causing mild carpal tunnel compression. Community reports consistently describe this in the first month. At 200 to 400 mcg of total blend, the effect is usually transient. If symptoms persist beyond two weeks after reducing the dose by half, stop the cycle. Carpal tunnel that won't resolve warrants medical evaluation.

Facial flushing right after injection is common in community reports and typically lasts 5 to 15 minutes. FDA's Category 2 page lists serious adverse events tied to CJC-1295, including increased heart rate and a systemic vasodilatory reaction. For ipamorelin, FDA cites serious adverse events, including death, in a published study of IV ipamorelin for gastric motility. Mild headache follows some users' early injections but rarely continues past the first week.

Published human safety data exists for each component individually, not the pre-mixed blend. CJC-1295 without DAC, the form in this blend, has no published human trial. Teichman et al. (2006)[2] tested CJC-1295 with DAC and reported no serious adverse reactions. Ipamorelin has human pharmacokinetic data from IV infusions in healthy men (Gobburu et al. 1999)[3]. Raun et al. (1998)[1] worked in rats and swine. No long-term safety study exceeding six months exists for either compound.

Community-reported issues beyond the above include vivid dreams (common, generally considered positive), occasional lightheadedness post-injection, and frustration with slow timelines. Meaningful body composition changes take a minimum of four to six weeks.

Cancer is an absolute contraindication. GH promotes cell proliferation. Active malignancy or a history of cancer rules out use. Active pituitary tumors and intracranial neoplasms also preclude use.

Diabetes mellitus is a contraindication. GH antagonizes insulin action and will worsen glycemic control in uncontrolled diabetics. Diabetic retinopathy adds further risk because GH and IGF-1 may accelerate retinal neovascularization.

Pregnancy and breastfeeding: absolute contraindication. No reproductive safety data exists for either component.

GH accelerates T4-to-T3 conversion. If you have subclinical hypothyroidism or take thyroid medication, monitor thyroid function mid-cycle.

When to stop: worsening fasting glucose, carpal tunnel persisting beyond two weeks at a reduced dose, edema unresponsive to dose reduction, or any new tumor diagnosis. When to see a doctor: IGF-1 above 400 ng/mL, glucose problems you can't resolve with dose changes, or any symptom that feels disproportionate.

Common Issues & Solutions

Water retention (edema in hands/wrists) during weeks 1–4: lower the dose by 25–50%; ensure empty stomach at injection; usually self-resolves. Persistent edema suggests GH-induced sodium retention: reduce to once-daily bedtime only.

No effect after 4+ weeks: most common cause is insufficient fasting window (food within 2 hours raises somatostatin); second cause is poor-quality or mislabeled peptide (DAC form sold as No DAC).

Tingling or numbness in fingers/hands: classic GH-mediated fluid shift causing mild carpal tunnel syndrome. Lower dose by 50%; if persists >2 weeks at reduced dose, stop the cycle.

Elevated fasting glucose: GH antagonizes insulin action; if fasting glucose rises >20 mg/dL from baseline, reduce dose or stop. Monitor HbA1c in pre-diabetic users.

DAC vs. No DAC confusion: the pre-mixed blend always uses No DAC (CJC-1295 without the Drug Affinity Complex); a certificate of analysis confirms which form is in the vial. DAC form should only be dosed 1–2x per week due to 6–8 day half-life: daily dosing of DAC form causes continuous non-pulsatile GH elevation.

Ask AI about this page

Ask AI for a second opinion on CJC-1295 + Ipamorelin dosing and side effects

Contraindications

  • Active cancer or history of malignancy: GH promotes cell proliferation
  • Diabetes mellitus: GH antagonizes insulin and may worsen glycemic control
  • Pregnancy or breastfeeding
  • Active pituitary tumors or other intracranial neoplasms
  • Hypersensitivity to GHRH analogs or ghrelin mimetics

Drug Interactions

  • Insulin and oral hypoglycemics: GH release antagonizes insulin action; blood glucose monitoring required
  • Corticosteroids: may blunt GH response and counteract benefits; chronic use reduces efficacy
  • Other GH secretagogues (GHRP-2, GHRP-6, sermorelin): additive GH release increases side effect risk; avoid stacking without medical supervision
  • Thyroid hormones: GH can accelerate T4-to-T3 conversion; monitor thyroid function
  • CYP450-metabolized drugs: GH may alter hepatic clearance of drugs metabolized by CYP3A4
  • Adding a second GHS-R1a agonist (GHRP-2) on top of Ipamorelin stacks two drugs on one receptor, with increased cortisol, prolactin, and appetite stimulation; raises IGF-1 unpredictably. Not recommended without medical supervision.
  • Same receptor competition/addition concern as GHRP-2 plus significant hunger amplification. Unlikely to add meaningful benefit over ipamorelin already in the blend.
  • CJC-1295 DAC has a 6–8 day half-life and is not dosed daily: combining with the No DAC blend creates dosing schedule confusion and unpredictable GHRH receptor stimulation duration.
  • MK-677 is a long-acting oral GHS-R1a agonist (t½ ~24h); stacking with Ipamorelin in this blend creates continuous receptor activation, negating the pulsatile GH release benefit and substantially elevating IGF-1 and cortisol. Common community mistake.

Product Quality

Recommended Monitoring

TestWhenTarget
IGF-1 (Insulin-Like Growth Factor 1)Baseline before starting; at week 8–12; after each cycleAge-adjusted normal range (typically 100–300 ng/mL depending on age); protocol target: upper-normal or slightly above for anti-aging; >400 ng/mL warrants dose reduction
Fasting glucose and fasting insulinBaseline; monthly during cycle, especially at higher dosesFasting glucose <100 mg/dL; HOMA-IR <2.0
HbA1cBaseline and end of each cycle if running multiple consecutive cycles<5.7%
Thyroid panel (TSH, Free T3, Free T4)Baseline; mid-cycle if symptomatic (fatigue, cold intolerance)Not listed
Blood pressureBaseline and monthly if stacking with anabolics or in hypertensive patientsNot listed
IGF-1 (Insulin-Like Growth Factor 1)

Primary downstream marker of GH axis activation; confirms biological response and detects supraphysiological elevation

Fasting glucose and fasting insulin

GH antagonizes insulin signaling; chronic GH elevation can induce insulin resistance (GH-mediated glucose intolerance)

HbA1c

Detects cumulative insulin resistance effects not visible in single fasting glucose readings

Thyroid panel (TSH, Free T3, Free T4)

GH accelerates T4-to-T3 conversion; may unmask subclinical hypothyroidism or require thyroid medication adjustment

Blood pressure

GH-induced sodium retention can elevate blood pressure, particularly in susceptible individuals

CJC-1295 + Ipamorelin Before and After

Week 1-2

Improved sleep quality and deeper REM cycles. Mild water retention possible as GH levels rise.

Weeks 3-4

Faster recovery from training. Skin and hair quality begin to improve. Increased energy and mood stability.

Months 2-3

Noticeable body composition changes: reduced abdominal fat, improved muscle tone. Joint and connective tissue recovery.

Months 3-4

Full anti-aging benefits emerge: improved skin elasticity, sustained fat loss, enhanced exercise capacity.

Month 5+

Benefits plateau. Cycle off for 4 weeks to maintain receptor sensitivity before restarting.

What to Expect

Week 1 to 2, sleep and early adaptation. GH pulses begin rising within hours of the first injection; in a human ipamorelin study, GH peaked about 40 minutes after dosing [3]. Most users notice deeper sleep and vivid dreams within seven to ten days. Mild water retention and facial flushing after injection are common. IGF-1 starts climbing by day three to five with repeated dosing.

Weeks 3 to 4, recovery picks up. Training recovery improves noticeably. Energy and mood stabilize. Skin texture starts changing. Water retention may peak around this point before beginning to resolve. GH-mediated fat oxidation has started, though body composition changes aren't visible yet.

Months 2 to 3, body recomposition becomes visible. Abdominal fat reduces. Muscle fullness improves. Joints and connective tissue feel noticeably better. Libido often improves. Sustained IGF-1 elevation is driving protein synthesis and lipolysis at the same time.

Months 3 to 4, peak benefits. Skin elasticity improves measurably. Hair and nail growth may pick up. Fat loss continues while lean mass holds. Side effects are typically minimal by this stage if the dose is well-calibrated.

Month 5 and beyond, benefits plateau. GHS-R1a desensitization becomes the limiting factor with uninterrupted use. Four weeks off allows receptor re-sensitization. Community users consistently report the next cycle works just as well after a proper break. Fat loss gains are largely retained during the off period; water-based lean mass may recede temporarily.

Detailed Timeline: Science vs Community

Week 1–2
Science

GH rises within an hour of a dose (IV ipamorelin peak ~40 min, PMID 10496658); IGF-1 begins rising by day 3–5 with repeated dosing

Community

Noticeably deeper sleep and vivid dreams are the most consistent early reports; mild water retention and bloating common

Weeks 3–4
Science

IGF-1 approaching new plateau; GH-mediated lipolysis initiated; protein synthesis upregulation beginning

Community

Faster recovery between training sessions; improved energy and mood; skin texture beginning to improve; water retention may persist or start resolving

Months 2–3
Science

Sustained IGF-1 elevation drives muscle protein synthesis; GH-mediated lipolysis (hormone-sensitive lipase activation) produces measurable fat loss

Community

Visible fat loss especially abdominal; improved muscle fullness; joint and connective tissue feel notably better; libido often improves

Months 3–4
Science

Maximum cumulative tissue response; anti-aging markers (skin elasticity, collagen synthesis) measurable

Community

Body composition changes most visible; hair and nail growth may accelerate; sustained fat loss with preserved lean mass; anti-aging effects become apparent

Month 5+ / Post-cycle
Science

GHS-R1a desensitization risk increases with uninterrupted use; 4-week off period allows receptor upregulation

Community

Benefits plateau; some regression of water-based lean mass when off; fat loss gains largely retained; users report next cycle works comparably after 4-week break

Pharmacokinetics

Half-Life
2h
Bioavailability
SC: not measured in humans for either component
Tmax
~40 minutes (GH peak after IV ipamorelin, PMID 10496658); no human data for CJC-1295 No DAC
Data Confidence
moderate

Source: Ipamorelin t½ ~2h drives dosing frequency (Gobburu et al. 1999, PMID 10496658); CJC-1295 No DAC t½ ~30 min (estimated, never measured in humans)

Pharmacokinetics: Active Dose Over Time

t½ = ~2 hours (ipamorelin); ~30 min (CJC-1295 no DAC, never measured in humans)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
34
Sequence
YADAIFTQSYRKVLAQLSARKLLQDILSRAHXFK
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: CJC-1295 No DAC: 863288-34-0; Ipamorelin: 170851-70-4

Who Should Consider CJC-1295 + Ipamorelin

  • Adults over 30 seeking anti-aging and recovery benefits
  • Athletes and bodybuilders optimizing body composition and recovery
  • Adults with age-related GH decline (somatopause)
  • Individuals with poor sleep quality seeking deeper restorative sleep
  • Post-injury patients wanting accelerated tissue repair

Related Peptides

What Changed for CJC-1295 + Ipamorelin

  1. Evidence

    Corrected Oct 17, 2026: CJC-1295 + ipamorelin's scientific confidence is now weak, not moderate; human CJC-1295 trials used DAC, per PubMed (PMID 16352683).

    Before: moderate After: weak

    What this does not mean: No new study was published, and the dose tiers are unchanged. Ipamorelin has its own human studies. PubMed lists no trial of this blend or of CJC-1295 without DAC.

    Source: J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  2. Evidence

    Corrected Oct 16, 2026: CJC-1295 + ipamorelin now reads Limited Research; the human CJC-1295 trials used the DAC form, per PubMed (PMID 16352683).

    Before: well-researched After: limited-research

    What this does not mean: Ipamorelin has its own human studies, and the dose tiers are unchanged. PubMed lists no trial of this blend or of CJC-1295 without DAC.

    Source: J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  3. Dosing

    Corrected Oct 14, 2026: the CJC-1295 trials dosed per kilogram with the DAC form, best tolerated at 30 or 60 mcg/kg, per PubMed (PMID 16352683).

    What this does not mean: The dose tiers on this page are unchanged. The page had listed trial doses as 30 to 300 mcg, which mixed per-kilogram doses with flat community doses.

    Source: J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  4. Safety

    Corrected Oct 14, 2026: CJC-1295 + ipamorelin side effects now list serious events, including raised heart rate and a death in an IV ipamorelin study, per FDA.

    Before: Flushing called common and benign; CJC-1295 said to have Phase I/II data; ipamorelin tolerability credited to Johansen 1999 and Raun 1998 After: Flushing reported as common in the community; FDA-cited serious events for CJC-1295 and IV ipamorelin listed; human CJC-1295 data credited to the DAC form; ipamorelin PK credited to Gobburu 1999

    What this does not mean: No new study. FDA's Category 2 page holds this text; FDA words them as 'associated with' and says clinical data are limited. Human CJC-1295 data come from the DAC form; the No DAC form in this blend has no published human trial.

    Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Sep 24, 20269 Citations

References

  1. [1]Ipamorelin, the First Selective Growth Hormone Secretagogue (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295 in Healthy Adults (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Advances in the detection of growth hormone releasing hormone synthetic analogs (Memdouh et al., Drug Test Anal 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry (J Pharm Biomed Anal 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin (Drug Test Anal 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Up to 12 months at 2-8°C; up to 24 months at -20°C, protected from light
After Reconstitution
Use within 21-28 days when stored at 2-8°C; do not freeze reconstituted solution
Temperature
2-8°C (36-46°F) reconstituted; -20°C for long-term lyophilized storage

Frequently Asked Questions

Community protocols run 200 to 1,200 mcg of total blend a day, in three tiers. Beginner is 200 mcg once daily, 4 units on a 100-unit insulin syringe after mixing a 10 mg vial with 2 mL bacteriostatic water. Moderate is 300 mcg once daily (6 units). Aggressive is 600 mcg twice daily, morning and bedtime, so 1,200 mcg a day at 12 units per injection. That exposure comes with IGF-1 monitoring in the advanced protocol below. These doses come from community practice. No study has tested the pre-mixed blend, and the human trials (CJC-1295 in its DAC form, IV ipamorelin) dosed by body weight (PMID 16352683, PMID 10496658).

Before bed on an empty stomach (2+ hours post-meal) is strongly preferred. GH releases its largest natural pulse in the first 1–2 hours of deep sleep; administering the peptides ~30 minutes before sleep amplifies this natural pulse rather than creating an artificial one at an off-time. Morning dosing on training days is used as an optional second injection by experienced users.

The 10 mg vial contains 5 mg CJC-1295 + 5 mg Ipamorelin. When reconstituted with 2 mL bac water, you get ~5,000 mcg/mL total. A 300 mcg total dose (the Moderate tier) = 0.06 mL (6 units on a 100-unit insulin syringe), so one vial provides about 33 doses.

Cycling off is strongly recommended. No clinical trial has tested 12–16 week cycles; that length comes from community practice. The concern is GHS-R1a desensitization, not pituitary suppression per se. Four weeks off appears sufficient to restore receptor sensitivity. Indefinite use without a break has not been studied.

Both peptides are on the WADA prohibited list (S2. Peptide Hormones and Related Substances). Anti-doping labs have built urine tests for CJC-1295 using spiked samples (PMID 34665524), and one was validated to WADA standards (PMID 41138283). A lab detected ipamorelin and its metabolites in urine after a nasal dose in one volunteer (PMID 25869809). Do not use if subject to athletic testing.